To receive your instant CME certificate, you must first
"Sign In" or "Sign Up" in the top right corner.
FORMAT: Monograph
RELEASE DATE: May 1, 2020
EXPIRATION DATE: May 31, 2021
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™
CLICK HERE TO PROCEED TO PROGRAM
ACTIVITY DESCRIPTION
Thrombotic microangiopathy (TMA) is a devastating complication that can follow hematopoietic stem cell transplantation (HSCT). The pathogenesis is complex, but endothelial damage leading to coagulation, aberrant immune activation, and complement activation are all thought to play a role. Recent research has shed light on the natural history of HSCT-TMA and early signs and tests that could be used as predictive screening tools. The landscape of treatment for HSCT-TMA is also evolving, as are best practices in stepwise, individualized treatment. In this activity, experts discuss these advances and how they might improve outcomes for affected patients. The desired results of this activity are to increase screening, identification, and timely treatment of HSCT-TMA and to build awareness of emerging treatments.
TARGET AUDIENCE
This educational activity is intended for hematologist oncologists and onco-nephrologists.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be better able to:
- Describe the pathogenesis and risk factors for HSCT-TMA
- Design evidence-based screening strategies for earlier detection of HSCT-TMA
- Contrast the clinical utility of current diagnostic criteria for HSCT-TMA
- Demonstrate ability to develop individualized, stepwise treatment strategies for patients with HSCT-TMA
- Interpret the clinical relevance of trial data for established and emerging therapies for HSCT-TMA
SATISFACTORY COMPLETION
Learners must pass a post-test and complete an evaluation form online. Upon passing, you will receive your certificate of completion immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this
activity has been planned and implemented by Amedco and MedEdicus LLC. Amedco
is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and
the American Nurses Credentialing Center (ANCC) to provide continuing education
for the healthcare team.
CREDIT DESIGNATION STATEMENT
Amedco designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
GRANTOR STATEMENT
This continuing medical education activity is supported through an unrestricted educational grant from Omeros Corporation.
DISCLOSURE OF CONFLICTS OF INTEREST
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1, 6.2, and 6.5)
All individuals in a position to control the content of CME are listed. If their name is not listed below, they disclosed that they had no relevant financial relationships.
|
First
|
Last | Company | Role |
| Edwin | Alyea | Omeros Corporation | Advisory Board |
| Christopher | Dvorak | Alexion Pharmaceuticals, Inc; and Jazz Pharmaceuticals Inc | Consultant |
| Vincent | Ho | Alexion Pharmaceuticals, Inc; Janssen Pharmaceuticals; Jazz Pharmaceuticals Inc; and Omeros Corporation | Consultant |
| Miguel-Angel | Perales | Bristol-Myers Squibb Company; Celgene Corporation; Incyte; Merck & Co., Inc; MolMed SpA; Nektar; NexImmune; Novartis Pharmaceuticals Corporation; Omeros Corporation; and Takeda Pharmaceuticals USA, Inc | Consultant |
| Gilead; Incyte; Kite Pharma; and Miltenyi Biotec | Contracted Research | ||
| Cidara Therapeutics, Inc; Medigene AG; and Servier Pharmaceuticals LLC | Other (Data Safety Monitoring Board) |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Amedco, MedEdicus LLC, or Omeros Corporation.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 211
PROCEED TO ACTIVITY